Nycomed, a Takeda company, has appointed Jostein Davidsen as its new Head of Emerging Markets.
Mr Davidsen will take on the post in addition to his current role as Area Head of Russia/CIS, reporting to Frank Morich, EVP, International Operations at Takeda Pharmaceuticals International, and CEO of Nycomed.
“Jostein’s strong track record of leading Russia/CIS over the past 17 years makes him an ideal candidate for this position,” said Mr Morich.
“His extensive knowledge of the industry, combined with vision and tenacity, has propelled Russia/CIS to become one of Nycomed’s top revenue contributors.”
Takeda’s acquisition of Nycomed in September 2011 was driven by Nycomed’s presence in Emerging Markets in Russia/CIS, Latin America, Middle East-Turkey-Africa and South Asia.
Takeda is a research-based global company with a main focus on pharmaceuticals. The combined company has an active commercial presence in the therapeutic areas of metabolic diseases, gastroenterology, oncology, cardiovascular health, CNS diseases, inflammatory and immune disorders, respiratory diseases and pain management.